Literature DB >> 505016

Clonal characteristics of experimentally induced "atherosclerotic" lesions in the hybrid hare.

T A Pearson, J Dillman, K J Williams, J A Wolff, R Adams, K Solez, R H Heptinstall, H Malmros, N Sternby.   

Abstract

The female hybrid hare (Lepus timidus x Lepus europaeus) is heterozygous for electrophoretically separable, X-linked isoenzymes of glucose-6-phosphate dehydrogenase. The isoenzymes of this animal have been used as cellular markers in the study of the clonal origins of experimentally induced atherosclerotic lesions. Aortic lesions produced in the hybrid hare by feeding cholesterol and injuring the aortic wall with a catheter have been shown to have polyclonal characteristics and in this way are fundamentally different from atherosclerotic fibrous plaques in man.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 505016     DOI: 10.1126/science.505016

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  4 in total

Review 1.  Macrophage Trafficking, Inflammatory Resolution, and Genomics in Atherosclerosis: JACC Macrophage in CVD Series (Part 2).

Authors:  Kathryn J Moore; Simon Koplev; Edward A Fisher; Ira Tabas; Johan L M Björkegren; Amanda C Doran; Jason C Kovacic
Journal:  J Am Coll Cardiol       Date:  2018-10-30       Impact factor: 24.094

2.  Reduction of atherosclerosis by administration of dehydroepiandrosterone. A study in the hypercholesterolemic New Zealand white rabbit with aortic intimal injury.

Authors:  G B Gordon; D E Bush; H F Weisman
Journal:  J Clin Invest       Date:  1988-08       Impact factor: 14.808

Review 3.  c-Myc oncoprotein: a dual pathogenic role in neoplasia and cardiovascular diseases?

Authors:  Claudio Napoli; Lilach O Lerman; Filomena de Nigris; Vincenzo Sica
Journal:  Neoplasia       Date:  2002 May-Jun       Impact factor: 5.715

4.  Lactate dehydrogenase (LDH) isozymes of human atherosclerotic plaques.

Authors:  A M Gown; E P Benditt
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.